-
Most Popular
Search Results
240 results for fsa
HUGE Stock Earnings: FSD Pharma Reported Results for Q1 2024
FSD Pharma just reported results for the first quarter of 2024.
Trade of the Day: Breakout Could Send ABX Stock Soaring
Barrick Gold Corporation (USA) is trading in a bullish consolidation pattern.
BioMimetic Has Suitors Lying in Wait
A key FDA OK could have the buyout offers rolling in.
It’s Time to Admit Defeat and Dump Ocugen Stock as a Covid Play
After the FDA rejected Covaxin, Ocugen has almost no chance of generating profits from the shot. OCGN stock is a great short.
Don’t Count Out Inovio Pharmaceuticals Stock Just Yet
INO stock is now a blood-in-the-street opportunity as Inovio is currently facing a temporary hurdle from the FDA.
Don’t Count on OTC Lipitor as an Rx for Higher PFE Stock
PFE stock holders are looking forward to cholesterol reducer Lipitor becoming an OTC drug, but Pfizer shareholders may have a long and disappointing wait.
Microsoft’s Big Win in the Government Cloud
Working with Computer Sciences, its FAA contract could be a game-changer — for the future of air-traffic control and for the battle in the cloud.
1 Billion Reasons Amazon.com, Inc. (AMZN) Blows Everyone Out of the Water
The AMZN stock price has gotten off to a rough start in 2016, but Fulfillment by Amazon (FBA) just provided 1 billion reasons to be…
Fisker (FSR) Stock Looks Primed for a Short Squeeze with 28% Short Interest
FSR stock commands a high short interest as a percentage of float as well as a high cost to borrow fee. Could shorts be squeezed…
PTC Therapeutics, Inc. (PTCT) Stock Tanks 30% After FDA Denies Its Appeal
PTCT stock suffered a heavy blow today, which came after the FDA denied PTC Therapeutics’ appeal concerning its muscular dystrophy drug.
One Big Problem Makes For One Big Opportunity In Fisker Stock
Fisker almost seems like the forgotten EV company amid still-present hype toward the sector. If and when that changes, FSR stock can rally.
CRSP Stock Alert: Can CRISPR Therapeutics Short Squeeze Higher?
CRSP stock is rallying after an FDA panel appeared to view CRISPR Therapeutics’ sickle-cell anemia treatment as safe.
The FAA Just Dealt a Huge Blow to United Airlines (UAL) Stock
UAL stock is sinking 5% after the FAA reported that it was cracking down on United Airlines for a string of safety incidents.
Ocugen Stock Still Looks Poised to Tumble
Ocugen’s apparent failure to prepare a U.S. trial for Covaxin, which will likely be necessary for FDA approval, bodes badly for OCGN stock.
Try a Small Position in Fisker Stock, but Monitor the EV Competition
Unless this electric vehicle manufacturer can rise above the rest, it’s going to be increasingly tough to defend a position in FSR stock.
Trade of the Day: ASA Ltd. Offering Attractive Entry Point
The recent pullback on profit-taking may be a good opportunity to buy ASA for the longer-term.
Fisker Is Working to Become a Heavenly Investment
Patience is a needed for owning FSR stock, but an optional collar spread should be required business for today’s investors
Feature-Rich Cars Could Power Fisker Stock to the Next Level
Even as FSR stock seeks direction, Fisker continue to move forward with truly unique, tech-enhanced and environmentally friendly vehicles.
Why Is Outlook Therapeutics (OTLK) Stock Down 78% Today?
Outlook Therapeutics (OTLK) stock is taking a beating on Wednesday after getting a rejection letter from the FDA for its wet AMD treatment..
Ben & Jerry’s CBD Ice Cream Is Coming: 11 Things We Know
Ben & Jerry’s CBD ice cream is in the works, but isn’t available yet due to some restrictions from the U.S. Food and Drug Administration.
Inovio Has Little to Show for Its Covid-19 Efforts
Inovio Pharmaceuticals has little to show for its Covid-19 efforts. INO stock is not worth more than $2, according to one short-seller.
5 Mutual Fund Safe Havens for Summer
Don’t sell in May and walk away completely — instead, pile some of your newfound cash into these five funds that should perform even during…
GMO Salmon: Genetically Engineered Fish Fights for Place on Your Plate
After four years of debate, the FDA still hasn’t approved the commercial sale of GMO salmon, and doesn’t appear to be near a final decision.
8 – 10 of 240 results
